

February 15, 2018

**To whom it may concern:**

Company Name TOHO HOLDINGS CO., LTD.  
 Corporate Representative Norio Hamada, Chairman of the Board and Representative Director  
 (First Section of Tokyo Stock Exchange Securities Code:8129)  
 Contact: Makoto Kawamura, Corporate Officer, General Manager, Public and Investor Relations Department  
 (TEL: 81-3-6838-2803)

**Notice Regarding Manufacture and Sales Approval of  
 1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters:Tokyo; President and Representative Director: Atsushi Udoh; hereinafter, “KYOSOMIRAI PHARMA”), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received an approval of manufacturing and sales for 1 ingredient / 2 products of generic drugs today on February 15, 2018 as below.

Products approved for manufacturing and sales

Class	Product Name	Original Brand Name
Phosphate binding agent	Lanthanum carbonate Granules 250mg / 500mg “KYOSOMIRAI”	Fosrenol Granules 250mg / 500mg

**KYOSOMIRAI PHARMA CO., LTD.**

KYOSOMIRAI PHARMA was established on November 1, 2016 as the wholly-owned subsidiary of TOHO HOLDINGS which engages in business such as pharmaceutical wholesaling, management of pharmacies, and development and provision of customer support systems under the corporate slogan, “Total commitment to good health”. KYOSOMIRAI PHARMA involves in development, manufacture and sales business of prescription pharmaceuticals centered on generic drugs as well as contracted manufacture of them. Establishing a business scheme of integrated manufacture and sales which accurately responds to customers’ demands, KYOSOMIRAI PHARMA aims to stably and effectively provide high quality and high value added prescription pharmaceuticals mainly for generic drugs.

**【Outline of KYOSOMIRAI PHARMA】**

Company Name KYOSOMIRAI PHARMA CO., LTD.  
 Head Office 1-4-4 Hiromachi, Shinagawa-ku, Tokyo 140-0005, Japan  
 Marunouchi Office GranTokyo South Tower 12F, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo100-6612, Japan  
 Executives Representative director and senior advisor: Norio Hamada  
 Representative director and chairman: Ryuzo Takada  
 Representative director and president: Atsushi Udoh  
 Business Contents Manufacture and sales of prescription pharmaceuticals,  
 Contracted manufacture of injectable pharmaceuticals